Anti-MAP3K7IP1/TAB1转化生长因子β活化激酶结合蛋白1抗体

询价
bioss
国产
2021-07-16 00:28

上海恪敏生物科技有限公司

我要认领
上海恪敏生物科技有限公司
王羽
18021003406
1914109725@qq.com
产品属性
应用范围WB,IHC-P,IHC-F,ICC,IF, Elisa
适应物种hu, mo, rat
宿主
是否单克隆2
抗体英文名Anti-MAP3K7IP1/TAB1
抗原来源详询
保质期1年
供应商上海科敏
保存条件-20℃
规格100ug
产品说明
本公司提供科研MAP3K7IP1/TAB1转化生长因子β活化激酶结合蛋白1抗体,抗体质量可靠,订购MAP3K7IP1/TAB1转化生长因子β活化激酶结合蛋白1抗体请联系在线客服或者销售人员。
抗体参数如下>>>>
中文名称:转化生长因子β活化激酶结合蛋白1抗体
英文名称:Anti-MAP3K7IP1/TAB1
货号:bs-4135R
抗体来源:兔
克隆类型:多克隆
蛋白分子量:predicted molecular weight: 55-60kDa
纯化方法:affinity purified by Protein A
交叉反应:hu, mo, rat
测试应用:ELISA=1:500-1000 IHC-P=1:100-500 IHC-F=1:100-500 IF=1:100-500
(石蜡切片需做抗原修复)
not yet tested in other applications.
optimal dilutions/concentrations should be determined by the end user.
产品背景介绍:TAB1 was identified as a regulator of the MAP kinase kinase kinase TAK1/MAP3K7, which is known to mediate various intracellular signaling pathways, such as those induced by TGF beta and members of the Toll IL 1R (TIR) superfamily, thus acting as an intermediate in both proliferative and innate and adaptive immune responses. This protein, together with either TAB2 or TAB3, activates TAK1 kinase in response to upstream signals. It has been shown that the C terminal portion of TAB1 is sufficient for binding and activation of TAK1, while a portion of the N terminus acts as a dominant negative inhibitor of TGF beta, demonstrating how this protein can function as a mediator between TGF beta receptors and TAK1.